Intellia Therapeutics Call to Discuss Interim Clinical Data From NTLA-2001 Phase 1 Study

Intellia will present additional interim clinical data from the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with polyneuropathy. The event will include a presentation by Ed Gane, MBChB, MD, FRACP, MNZM, Professor of Medicine at the University of Auckland, New Zealand and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital and an investigator in the ongoing NTLA-2001 Phase 1 study, along with members of Intellia's management team.
To join the webcast, please visit this linkexternal link, opens in a new tab.
Date & Time:
February 28, 2022
4:30 PM EST

This event has ended.